Patent intelligence · US
US 11192923
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
Patent details — US 11192923
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 7, 2021
- Expiration
- Dec 2, 2041
- Applicant
- Theradaptive, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K38/00, A61K38/04, A61K38/16
Quick answer
US 11192923 (Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof) is held by Theradaptive, Inc.. Status: granted. Granted Dec 7, 2021. Expires Dec 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theradaptive, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K38/00, A61K38/04, A61K38/16, A61K38/1875, A61P
More from Theradaptive, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12264187
Compositions and methods for targeted therapeutic delivery to bone
granted -
US 12263179
Lyme disease-associated T cell receptor-related methods
granted -
US 12266425
T cell receptor sequences diagnostic for COVID-19 and related compositions
granted -
US 12006517
Method for purification of bacteriophage particles
granted -
US 11911345
Phage dispensing system
granted -
US 11773138
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted -
US 11390921
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
granted
Frequently asked questions
What is US patent 11192923?
US 11192923 (Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof) is held by Theradaptive, Inc.. Status: granted. Granted Dec 7, 2021. Expires Dec 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11192923?
Theradaptive, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 11192923 expire?
Our index shows an expiration date of Dec 2, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.